This document discusses the development of biochips for analyzing metabolic imbalances in humans. It notes that 350 million people have diabetes worldwide and there is an urgent need for reliable disease prediction and risk assessment. The proposed solution is biochips that can quantitatively measure glycated hemoglobin and albumin levels using surface-enhanced Raman scattering (SERS) for highly sensitive detection. The biochips would be inexpensive, noninvasive, and easy to use. A team is presented that would develop and test the biochips over a 6 year period, with the goal of licensing the technology to diagnostic companies in years 3-6.

1. Biochips for express analysis of
metabolic imbalance in human’s
body
R&D Bioplasmonics

2. Objectives
Problem
350 million diabetes patients in the world
Urgent necessity: Reliable prediction of diseases
and risk of unfavorable outcome of disease
Solution
Biochips: Quantitative information
 glycated hemoglobin level
 glycated albumin level

3. Market

4. Market

5. Point-of-care HbA1c testing segment.
 Ion Exchange Chromatography
(Bio-Rad, Drew et al.)
 High-Performance Liquid
Chromatography (HPLC)
 Boronate Affinity Chromatography
(EKFdiagnostics/Que-Test)
 Immunoassay Method (Bayer,
Beckman, Coulter, Olympus,
Roche, Diazyme/GlycoGap et al.)
* Capillarys-2 Flex Piercing, Sebia
Quo-Test

6. SERS Biochips
 Raman spectroscopy
 Nanoplasmonics
 Biotechnology
Surface-Enhanced
Raman Scattering (SERS)
Raman spectroscopy = fingerprint of molecules
Additional signal
enhancement over 107

7. SERS Biochips
PDDA
Au nanoparticles
HbA1c
Phenylboronic acid
Regular
dielectric films
Facet dielectric films
Metallic clusters
High-sensitive biochip

8. Advantages
 High sensitivity (SERS signal >107) => Low concentration
detection (1-2 ng/ml)!
 Noninvasive analyze
 No sample preparation and simple exploitation
 Flexibility
 Cheap price
Product Enhancement Background
signal
Price
Project SERS substrates 107 low 10$
Ranishaw Diagnostics (UK)/ Klarite 104-106 high $500 for 5
Silmeco/SERStrate 104 low $315 for 5
Diagnostic anSERS Inc./P-SERS 105 low $45 for 6

9. Applications
Cell Culture (DMEM)
 Diagnostics of diabetes, renal
disease,hypothyroidism
 Identification of cancer markers
(in future): oncology
Glycated hemoglobin and albumin
After cancer
cell cultivation
Before cancer
cell cultivation

10. Team
Andrey Sarychev  CEO, PhD, Dr. Sci., Professor
 Supervision, design and implementation of biochips
 Experience of research in material science, plasmonics,
antenna design, optical chemical and biosensors
Andrey Ivanov  R&D, PhD
 Design and optimization of biochips
 Experience of science research in plasmonics
Tatyana Karmakova  Сlinician, PhD, Dr. Sci.
 Clinical research and testing
 Experience of cancer processes research
Maria Shcherbak  Manager, PhD
 Customer relations. Fundraising
 Experience of successful startups (LumInnoTech LLC,
HandyPower LLC).

11. Project development plan
Stage 1
Development of
industrial designs
Stage 2
Biochips development,
testing
Stage 3
Sale of licenses (Ranishaw,
Silmeco, Diagnostics an
SERS Inc.)/
Manufacturing of biochips,
software, sales
Requirement:
— Investment – 20 million rubles
— Partner – producer of diagnostics spectral devices
1 year 2 year 3 year 4 year 5 year 6 year
Proceeds (biochips
without test systems),
thousands of rubles
0 0 7 189 55 494 67 107 68 523